Alkermes reiterated at buy by Merrill

Merrill Lynch analyst Hari Sambasivam reiterated Alkermes, Inc. at buy as the company reported better-than-expected fourth-quarter 2006 results. Total revenues of $53.7 million beat the analyst's expectations of $42.5 million. Alkermes provided guidance for 2007, including total revenues of $200 million to $222 million, Vivitrol sales of $35 million to $45 million and earnings per share of $0.05 to $0.10. Shares of the Cambridge, Mass., pharmaceutical company were up 27 cents, or 1.37%, at $19.93 on volume of 3,161,113 shares versus the three-month running average of 1,693,390 shares. (Nasdaq: ALKS)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.